Considering that IGFBP2 is a hepatokine, which shows strong effects on the regulation of lipid metabolism, we estimated the degree of hepatic steatosis in patients with MASLD using CAP value from FibroScan and conducted a correlation analysis to investigate whether the serum level of IGFBP2 is associated with the degree of hepatic steatosis in patients with MASLD. This evidence concerns the gene IGFBP2 and Hepatic steatosis.